Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Boston, MA
SEC filing record 1 source field available
Fiscal year end
31 December
Verve Therapeutics, Inc. has filed 344 SEC EDGAR filings since 22 Jan 2021

SEC filing history

Showing 176-200 of 344 matching filings.

Per page
25
Current page
8
SC 13G/A File 005-92605

ARCH VENTURE FUND X, L.P. - VERVE THERAPEUTICS, INC. -- SCH 13G/A(#1E)

Filing date
13 Feb 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-92605

SC 13G/A

Filing date
10 Feb 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-92605

SC 13G filing

Filing date
10 Feb 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-92605

SC 13G

Filing date
10 Feb 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-92605

SC 13G/A filing

Filing date
09 Feb 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-92605

SCHEDULE 13G

Filing date
09 Feb 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-92605

SC 13G filing

Filing date
07 Feb 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-92605

SEC SCHEDULE 13G

Filing date
06 Feb 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
16 Dec 2022
Reporting date
14 Dec 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
02 Dec 2022
Reporting date
01 Dec 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
01 Dec 2022
Reporting date
29 Nov 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
08 Nov 2022
Reporting date
04 Nov 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
08 Nov 2022
Reporting date
04 Nov 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
04 Nov 2022
Reporting date
02 Nov 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
04 Nov 2022
Reporting date
02 Nov 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
02 Nov 2022
Reporting date
31 Oct 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
02 Nov 2022
Reporting date
31 Oct 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
01 Nov 2022
Reporting date
28 Oct 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
05 Oct 2022
Reporting date
03 Oct 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
27 Sep 2022
Reporting date
23 Sep 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
S-3ASR File 333-267578

S-3ASR

Filing date
23 Sep 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
29 Aug 2022
Reporting date
25 Aug 2022
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .